TSHA stock forecast
Our latest prediction for Taysha Gene Therapies Inc's stock price was made on the Nov. 22, 2023 when the stock price was at 1.84$.
In the short term (2weeks), TSHA's stock price should underperform the market by -1.62%. During that period the price should oscillate between -10.82% and +6.17%.
In the medium term (3months), TSHA's stock price should outperform the market by 1.47%. During that period the price should oscillate between -31.49% and +10.61%.
Get email alertsCreate a solid portfolio with TSHA
About Taysha Gene Therapies Inc
taysha gene therapies, inc., a gene therapy company, develops adeno-associated virus based gene therapies for the treatment of monogenic diseases of the central nervous system. it primarily develops tsha-101 for the treatment of gm2 gangliosidosis; tsha-118 for the treatment of cln1 disease; tsha-102 for the treatment of rett syndrome; tsha-103 for the treatment of slc6a1 haploinsufficiency disorder; and tsha-104 for the treatment for surfeit locus 1 deficiency. the company also has strategic partnership with the university of texas southwestern medical center to develop and commercialize transformative gene therapy treatments. taysha gene therapies, inc. was founded in 2019 and is based in dallas, texas.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -2.85$ per share.
The book value per share is 5.88$
Three months stock forecastNov. 22, 2023
Financials
| Revenue USD | Gross Margin | Operating Income | Operating Margin | Net Income | Earnings Per Share | Dividends | Payout Ratio | Shares | Book Value Per Share | Operating Cash Flow | Cap Spending | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -111M | - | -215M | -2.85 | - | - | 186M | 5.88 | - | - | - |